Combined Raloxifene and Letrozole for Breast Cancer Patients
Raloxifene, an anti-osteoporotic drug, is recently approved for prevention of breast cancer in postmenopausal women and thus the drug may be employed to combat the bony adverse effects of letrozole, another anticancer drug. However, the cytotoxic effect of their combination on human breast cancer (MCF-7) and human embryonic kidney (HEK) cell lines is not known. MCF-7 and HEK cell lines were treated with different graded doses of letrozole, raloxifene and their combination, then incubated for 24 –48 h.
Source: Archives of Medical Research - Category: Research Authors: Divya Vohora, Abul Kalam, Ankita Leekha, Sushama Talegaonkar, Anita Kamra Verma Tags: Preliminary Report Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Evista | Research | Urology & Nephrology | Women